Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
Publication/Presentation Date
6-1-2022
Abstract
AIM: Evaluate the efficacy and safety of non-invasive vagus nerve stimulation for migraine prevention.
METHODS: After completing a 4-week diary run-in period, adults who had migraine with or without aura were randomly assigned to receive active non-invasive vagus nerve stimulation or sham therapy during a 12-week double-blind period.
RESULTS: Of 336 enrolled participants, 113 (active, n = 56; sham, n = 57) completed ≥70 days of the double-blind period and were ≥66% adherent with treatment, comprising the prespecified modified intention-to-treat population. The COVID-19 pandemic led to early trial termination, and the population was ∼60% smaller than the statistical target for full power. Mean reduction in monthly migraine days (primary endpoint) was 3.12 for the active group and 2.29 days for the sham group (difference, -0.83;
CONCLUSIONS: These results suggest clinical utility of non-invasive vagus nerve stimulation for migraine prevention, particularly for patients who have migraine with aura, and reinforce the well-established safety and tolerability profile of this therapy.
Volume
42
Issue
7
First Page
560
Last Page
569
ISSN
1468-2982
Published In/Presented At
Najib, U., Smith, T., Hindiyeh, N., Saper, J., Nye, B., Ashina, S., McClure, C. K., Marmura, M. J., Chase, S., Liebler, E., & Lipton, R. B. (2022). Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Cephalalgia : an international journal of headache, 42(7), 560–569. https://doi.org/10.1177/03331024211068813
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35001643
Department(s)
Administration and Leadership
Document Type
Article